Leveraging RNA Analytics and AI to Deliver Personalized, Effective Treatments for Complex Conditions
At the 2024 Precision Health Summit, Amrie Grammer, Founder, President, and Chief Scientific Officer of AMPEL Biosolutions, presents a vision of how precision medicine can reshape autoimmune and inflammatory disease treatment.
AMPEL develops a blood test for cardiovascular disease
Armie Grammer, AMPEL’s co-founder, president, and chief scientific officer of AMPEL BioSolutions, explains the company’s CardioGENE blood test for cardiovascular disease risk.
New Blood Test Can Predict Heart Disease and Guide Prophylactic Treatment
AMPEL BioSolutions’ new CardioGENE blood test predicts heart disease by identifying genetic markers and inflammatory pathways, enabling personalized, preventive therapies.
Precision Medicine Blood Test Predicts Heart Disease Before It Occurs
A precision medicine blood test can predict heart disease before it happens and provide decision support for prophylactic therapies.
AMPEL BioSolutions: Precision Medicine Blood Testing Predicts Heart Disease and Therapeutic Intervention
AMPEL BioSolutions announced a precision medicine blood test that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.